Primary cells, human ECM & 3D technologies for ADMET

Preci’s DMPK products use high-quality human hepatocytes, liver microsomes, and subcellular fractions to support precise and reproducible drug metabolism and pharmacokinetic studies. Strict quality control and single-donor or pooled batches ensure reliable data on clearance, toxicity, and drug-drug interactions. Specialized reagents and consumables streamline complex workflows for consistent, actionable results.

Leveraging its extensive clinical sourcing capabilities, Preci has developed a comprehensive platform capable of generating a variety of disease models. These models are supported by detailed histological and molecular data, along with drug action profiles. Through this platform, we can offer researchers access to multiple disease models, seamlessly transferring them for their studies. 

Preci’s portfolio supports research in Type 2 Diabetes, NASH, and organ fibrosis with high-quality human primary cells and specialized ECM hydrogels. Sourced from healthy and disease-state donors, these models replicate key metabolic and fibrotic mechanisms, enabling reproducible studies of insulin resistance, fibrosis progression, and therapeutic response.

Preci’s immunology portfolio delivers high-quality primary human immune cells—PBMCs, T-cells, B-cells, and immune dendritic cells (IDC) —sourced from both healthy and disease-state donors. Our end-to-end workflow—from donor recruitment and ethical consent through isolation, quality control, and cryopreservation—ensures reproducible performance in your functional assays, co-culture studies, and drug screening campaigns.